Date of this Version
7-2019
Document Type
Article
Abstract
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive medications. They are indicated in the management of multiple chronic conditions including hypertension, diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis. The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Asgharpour, Masoumeh; Kalan, Mohammad Ebrahimi; Mirhashemi, Seyed Hadi; and Alirezaei, Amirhesam, "Lung cancer risk and the inhibitors of angiotensinconverting enzyme: A mini-review of recent evidence" (2019). Department of Epidemiology. 37.
https://digitalcommons.fiu.edu/epidemiology/37
Rights Statement
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
Comments
Originally published in Immunopathologia Persa.